A5332: Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Study Location:

BaltimoreIndia

Topic:

Cardiovascular Disease and HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02344290?term=a5332&rank=1

IRB#:

Pro00011068

Coordinator:

Anna Wimpelberg (Washington)

Ilene Wiggins, RN (Baltimore)

Nishi Suryavanshi (India)

Enrollment:

Closed

Trial Period:

Ongoing

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months. The trial is testing the effect of statin therapy on preventing heart disease and death in HIV-infected persons on HIV medications who do not meet guidelines for starting statins.       

  • HIV infected men and women between the ages of 40 and 75
  • On HIV medications for at least 6 months
  • CD4 cell count greater than 100
  • No history of cardiovascular disease, such as heart attack, stroke, etc.
  • No history of cancer in the last 3 years
  • Not currently using a statin drug

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More